Zacks: Brokerages Anticipate Viking Therapeutics Inc (VKTX) Will Announce Earnings of -$0.12 Per Share

Equities research analysts expect Viking Therapeutics Inc (NASDAQ:VKTX) to report earnings per share of ($0.12) for the current quarter, Zacks reports. Zero analysts have made estimates for Viking Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.10) and the lowest estimate coming in at ($0.14). Viking Therapeutics posted earnings of ($0.21) per share during the same quarter last year, which indicates a positive year over year growth rate of 42.9%. The business is expected to report its next quarterly earnings report on Wednesday, August 8th.

According to Zacks, analysts expect that Viking Therapeutics will report full-year earnings of ($0.45) per share for the current year, with EPS estimates ranging from ($0.51) to ($0.41). For the next financial year, analysts forecast that the firm will report earnings of ($0.52) per share, with EPS estimates ranging from ($0.70) to ($0.43). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side analysts that cover Viking Therapeutics.

Viking Therapeutics (NASDAQ:VKTX) last released its quarterly earnings results on Wednesday, May 9th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.12) by $0.02.

Several equities research analysts recently issued reports on the stock. HC Wainwright set a $11.00 target price on shares of Viking Therapeutics and gave the stock a “buy” rating in a research report on Thursday, May 10th. Maxim Group set a $8.00 target price on shares of Viking Therapeutics and gave the stock a “buy” rating in a research report on Thursday, May 10th. ValuEngine raised shares of Viking Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, April 2nd. William Blair assumed coverage on shares of Viking Therapeutics in a research report on Monday, April 30th. They issued an “outperform” rating on the stock. Finally, BidaskClub cut shares of Viking Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, March 16th. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $14.25.

Shares of VKTX traded up $0.44 during mid-day trading on Friday, hitting $11.08. The company had a trading volume of 7,682,711 shares, compared to its average volume of 2,439,684. Viking Therapeutics has a 1-year low of $0.88 and a 1-year high of $13.43. The stock has a market capitalization of $626.99 million, a PE ratio of -14.03 and a beta of 2.77.

In other Viking Therapeutics news, Director J Matthew Singleton purchased 9,500 shares of Viking Therapeutics stock in a transaction on Thursday, May 31st. The shares were purchased at an average cost of $9.82 per share, with a total value of $93,290.00. Following the completion of the transaction, the director now directly owns 9,500 shares in the company, valued at approximately $93,290. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Michael Morneau sold 21,551 shares of Viking Therapeutics stock in a transaction that occurred on Thursday, May 31st. The shares were sold at an average price of $9.25, for a total transaction of $199,346.75. Following the transaction, the vice president now directly owns 94,035 shares in the company, valued at $869,823.75. The disclosure for this sale can be found here. 3.90% of the stock is currently owned by company insiders.

A number of hedge funds have recently made changes to their positions in VKTX. Victory Capital Management Inc. acquired a new position in Viking Therapeutics during the fourth quarter valued at approximately $791,000. Opaleye Management Inc. acquired a new position in Viking Therapeutics during the fourth quarter valued at approximately $1,951,000. Sphera Funds Management LTD. lifted its position in Viking Therapeutics by 639.8% during the fourth quarter. Sphera Funds Management LTD. now owns 2,145,300 shares of the biotechnology company’s stock valued at $8,710,000 after buying an additional 1,855,300 shares in the last quarter. Cornerstone Capital Inc. acquired a new position in Viking Therapeutics during the fourth quarter valued at approximately $352,000. Finally, EAM Investors LLC acquired a new position in Viking Therapeutics during the fourth quarter valued at approximately $2,538,000. 41.05% of the stock is currently owned by hedge funds and other institutional investors.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead clinical program, VK5211, is an orally available, non-steroidal selective androgen receptor modulator in Phase II development for the treatment of patients recovering from non-elective hip fracture surgery; in Phase I clinical trials for improving lean body mass; and in pre-clinical trial for improving bone mineral density, bone mineral content, bone strength, and other measures.

Get a free copy of the Zacks research report on Viking Therapeutics (VKTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Viking Therapeutics (NASDAQ:VKTX)

Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply